Alvotech Holdings S.A.: Alvotech and STADA Pave Way to Launching HUKYNDRA(AVT02), a Citrate-free, High-concentration Biosimilar to Humira by Resolving European Patent Dispute With AbbVie
Upon launch, HUKYNDRA will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market All intellectual-property disputes related to market entry of Alvotech's